Alcohol addiction - the safety of available approved treatment options

Mariangela Antonelli, Anna Ferrulli, Luisa Sestito, Gabriele A. Vassallo, Claudia Tarli, Carolina Mosoni, Maria M. Rando, Antonio Mirijello, Antonio Gasbarrini, Giovanni Addolorato

Research output: Contribution to journalReview article

11 Citations (Scopus)

Abstract

Introduction: Alcohol Use Disorders (AUD) is a leading cause of mortality and morbidity worldwide. At present disulfiram, naltrexone and acamprosate are approved for the treatment of AUD in U.S. and Europe. Nalmefene is approved in Europe and sodium oxybate is approved in Italy and Austria only. Baclofen received a ‘temporary recommendation for use’ in France. Areas covered: The safety of the above mentioned medications on liver, digestive system, kidney function, nervous system, pregnancy and lactation and their possible side effects are described and discussed. Expert opinion: Mechanism of action and metabolism of these drugs as well as patients’ clinical characteristics can affect the safety of treatment. All approved medications are valid tools for the treatment of AUD in patients without advanced liver disease. For some drugs, attention should be paid to patients with renal failure and medications may be used with caution, adjusting the dosage according to kidney function. In patients with AUD and advanced liver disease, at present only baclofen has been formally tested in randomized controlled trials showing its safety in this population.

Original languageEnglish
Pages (from-to)169-177
Number of pages9
JournalExpert Opinion on Drug Safety
Volume17
Issue number2
DOIs
Publication statusPublished - Feb 1 2018

Fingerprint

Alcoholism
Alcohols
Safety
Baclofen
Liver Diseases
Sodium Oxybate
Kidney
Disulfiram
Digestive System
Naltrexone
Austria
Expert Testimony
Therapeutics
Lactation
Pharmaceutical Preparations
Nervous System
Italy
France
Renal Insufficiency
Randomized Controlled Trials

Keywords

  • Alcohol
  • alcohol dependence
  • AUD
  • craving
  • safety

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Antonelli, M., Ferrulli, A., Sestito, L., Vassallo, G. A., Tarli, C., Mosoni, C., ... Addolorato, G. (2018). Alcohol addiction - the safety of available approved treatment options. Expert Opinion on Drug Safety, 17(2), 169-177. https://doi.org/10.1080/14740338.2018.1404025

Alcohol addiction - the safety of available approved treatment options. / Antonelli, Mariangela; Ferrulli, Anna; Sestito, Luisa; Vassallo, Gabriele A.; Tarli, Claudia; Mosoni, Carolina; Rando, Maria M.; Mirijello, Antonio; Gasbarrini, Antonio; Addolorato, Giovanni.

In: Expert Opinion on Drug Safety, Vol. 17, No. 2, 01.02.2018, p. 169-177.

Research output: Contribution to journalReview article

Antonelli, M, Ferrulli, A, Sestito, L, Vassallo, GA, Tarli, C, Mosoni, C, Rando, MM, Mirijello, A, Gasbarrini, A & Addolorato, G 2018, 'Alcohol addiction - the safety of available approved treatment options', Expert Opinion on Drug Safety, vol. 17, no. 2, pp. 169-177. https://doi.org/10.1080/14740338.2018.1404025
Antonelli, Mariangela ; Ferrulli, Anna ; Sestito, Luisa ; Vassallo, Gabriele A. ; Tarli, Claudia ; Mosoni, Carolina ; Rando, Maria M. ; Mirijello, Antonio ; Gasbarrini, Antonio ; Addolorato, Giovanni. / Alcohol addiction - the safety of available approved treatment options. In: Expert Opinion on Drug Safety. 2018 ; Vol. 17, No. 2. pp. 169-177.
@article{5778c79f7c344783b8acbdf0b2a4c918,
title = "Alcohol addiction - the safety of available approved treatment options",
abstract = "Introduction: Alcohol Use Disorders (AUD) is a leading cause of mortality and morbidity worldwide. At present disulfiram, naltrexone and acamprosate are approved for the treatment of AUD in U.S. and Europe. Nalmefene is approved in Europe and sodium oxybate is approved in Italy and Austria only. Baclofen received a ‘temporary recommendation for use’ in France. Areas covered: The safety of the above mentioned medications on liver, digestive system, kidney function, nervous system, pregnancy and lactation and their possible side effects are described and discussed. Expert opinion: Mechanism of action and metabolism of these drugs as well as patients’ clinical characteristics can affect the safety of treatment. All approved medications are valid tools for the treatment of AUD in patients without advanced liver disease. For some drugs, attention should be paid to patients with renal failure and medications may be used with caution, adjusting the dosage according to kidney function. In patients with AUD and advanced liver disease, at present only baclofen has been formally tested in randomized controlled trials showing its safety in this population.",
keywords = "Alcohol, alcohol dependence, AUD, craving, safety",
author = "Mariangela Antonelli and Anna Ferrulli and Luisa Sestito and Vassallo, {Gabriele A.} and Claudia Tarli and Carolina Mosoni and Rando, {Maria M.} and Antonio Mirijello and Antonio Gasbarrini and Giovanni Addolorato",
year = "2018",
month = "2",
day = "1",
doi = "10.1080/14740338.2018.1404025",
language = "English",
volume = "17",
pages = "169--177",
journal = "Expert Opinion on Drug Safety",
issn = "1474-0338",
publisher = "Taylor and Francis Ltd.",
number = "2",

}

TY - JOUR

T1 - Alcohol addiction - the safety of available approved treatment options

AU - Antonelli, Mariangela

AU - Ferrulli, Anna

AU - Sestito, Luisa

AU - Vassallo, Gabriele A.

AU - Tarli, Claudia

AU - Mosoni, Carolina

AU - Rando, Maria M.

AU - Mirijello, Antonio

AU - Gasbarrini, Antonio

AU - Addolorato, Giovanni

PY - 2018/2/1

Y1 - 2018/2/1

N2 - Introduction: Alcohol Use Disorders (AUD) is a leading cause of mortality and morbidity worldwide. At present disulfiram, naltrexone and acamprosate are approved for the treatment of AUD in U.S. and Europe. Nalmefene is approved in Europe and sodium oxybate is approved in Italy and Austria only. Baclofen received a ‘temporary recommendation for use’ in France. Areas covered: The safety of the above mentioned medications on liver, digestive system, kidney function, nervous system, pregnancy and lactation and their possible side effects are described and discussed. Expert opinion: Mechanism of action and metabolism of these drugs as well as patients’ clinical characteristics can affect the safety of treatment. All approved medications are valid tools for the treatment of AUD in patients without advanced liver disease. For some drugs, attention should be paid to patients with renal failure and medications may be used with caution, adjusting the dosage according to kidney function. In patients with AUD and advanced liver disease, at present only baclofen has been formally tested in randomized controlled trials showing its safety in this population.

AB - Introduction: Alcohol Use Disorders (AUD) is a leading cause of mortality and morbidity worldwide. At present disulfiram, naltrexone and acamprosate are approved for the treatment of AUD in U.S. and Europe. Nalmefene is approved in Europe and sodium oxybate is approved in Italy and Austria only. Baclofen received a ‘temporary recommendation for use’ in France. Areas covered: The safety of the above mentioned medications on liver, digestive system, kidney function, nervous system, pregnancy and lactation and their possible side effects are described and discussed. Expert opinion: Mechanism of action and metabolism of these drugs as well as patients’ clinical characteristics can affect the safety of treatment. All approved medications are valid tools for the treatment of AUD in patients without advanced liver disease. For some drugs, attention should be paid to patients with renal failure and medications may be used with caution, adjusting the dosage according to kidney function. In patients with AUD and advanced liver disease, at present only baclofen has been formally tested in randomized controlled trials showing its safety in this population.

KW - Alcohol

KW - alcohol dependence

KW - AUD

KW - craving

KW - safety

UR - http://www.scopus.com/inward/record.url?scp=85041098595&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85041098595&partnerID=8YFLogxK

U2 - 10.1080/14740338.2018.1404025

DO - 10.1080/14740338.2018.1404025

M3 - Review article

VL - 17

SP - 169

EP - 177

JO - Expert Opinion on Drug Safety

JF - Expert Opinion on Drug Safety

SN - 1474-0338

IS - 2

ER -